Risk Factors Associated With Thrombocytopenia Induced by Intravenous Immunoglobulin Formulations: An Analysis Using the JADER database
Open Access
- 27 June 2025
- journal article
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 39 (4) , 2320-2327
Abstract
Thrombocytopenia is a serious adverse event observed with intravenous immunoglobulin formulations (IVIg). There have been some individual case reports of such events, but to our knowledge, no epidemiological studies have been reported. In this study, the risk of IVIg-induced thrombocytopenia and factors associated with IVIg-induced thrombocytopenia were examined using the Japanese Adverse Drug Event Report database. Data spanning from April 2004 to August 2024 were used. The association between IVIg and thrombocytopenia was evaluated using the reporting odds ratio (ROR). The reports of IVIg-induced thrombocytopenia events were evaluated by disease and aggregated by disease group. Factors associated with IVIg-induced thrombocytopenia were detected using multiple logistic regression with age, sex, formulation method, and disease group as explanatory variables and adjusted RORs were calculated. The IVIgs examined were significantly associated with thrombocytopenia. Pemphigoid was the most frequently reported disease, followed by Kawasaki disease and polymyositis/dermatomyositis. Immune-mediated skin diseases were the most frequently reported disease group, followed by Kawasaki disease, immune-mediated neurological diseases, and immune-mediated muscular diseases. Multiple logistic regression analysis showed that at age 60 years or older, immune-mediated skin diseases and immune-mediated muscular diseases were independently associated with significantly increased RORs. This study suggests that IVIg can induce thrombocytopenia and that thrombocytopenia should be assessed in patients with immune-mediated skin diseases, immune-mediated muscular diseases and in the elderly.Keywords
This publication has 17 references indexed in Scilit:
- Macrophage activation syndrome in Kawasaki Disease: More common than we thought?Seminars in Arthritis and Rheumatism, 2015
- Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in FranceBlood, 2014
- Thrombocytopenia in Kawasaki disease: a risk factor for the development of coronary artery aneurysms.2003
- Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulinsSpringer Seminars in Immunopathology, 2001
- The Bleeding Risk and Natural History of Idiopathic Thrombocytopenic Purpura in Patients With Persistent Low Platelet CountsArchives of internal medicine (1960), 2000
- Thrombocytopenia and prognosis in intensive careCritical Care Medicine, 2000
- The Incidence of Idiopathic Thrombocytopenic Purpura in Adults Increases With AgeBlood, 1999
- [Marked thrombocytopenia after high-dose intravenous gamma globulin in a pregnant woman with idiopathic thrombocytopenic purpura].1999
- Thrombocytopenia: a risk factor for acute myocardial infarction during the acute phase of Kawasaki disease.1995
- Thrombocytopenia: a complication of Kawasaki diseaseEuropean Journal of Pediatrics, 1988